Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYN NASDAQ:ETON NASDAQ:HRMY NASDAQ:IMCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$13.13-5.7%$11.58$6.36▼$37.04$1.87B1.12.58 million shs1.06 million shsETONEton Pharmaceuticals$18.31-0.8%$16.26$5.35▼$21.48$492.11M1.1350,385 shs188,725 shsHRMYHarmony Biosciences$32.52-0.3%$35.56$26.47▼$41.61$1.87B0.84663,583 shs547,825 shsIMCRImmunocore$32.59-2.5%$33.98$23.15▼$39.33$1.65B0.77330,468 shs46,073 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics+5.86%+5.61%+13.63%+34.88%-59.46%ETONEton Pharmaceuticals+4.41%+5.07%+13.95%+36.04%+212.35%HRMYHarmony Biosciences+1.78%-2.36%-10.36%+2.32%-14.89%IMCRImmunocore0.00%-8.61%+3.34%+6.64%-2.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$13.13-5.7%$11.58$6.36▼$37.04$1.87B1.12.58 million shs1.06 million shsETONEton Pharmaceuticals$18.31-0.8%$16.26$5.35▼$21.48$492.11M1.1350,385 shs188,725 shsHRMYHarmony Biosciences$32.52-0.3%$35.56$26.47▼$41.61$1.87B0.84663,583 shs547,825 shsIMCRImmunocore$32.59-2.5%$33.98$23.15▼$39.33$1.65B0.77330,468 shs46,073 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics+5.86%+5.61%+13.63%+34.88%-59.46%ETONEton Pharmaceuticals+4.41%+5.07%+13.95%+36.04%+212.35%HRMYHarmony Biosciences+1.78%-2.36%-10.36%+2.32%-14.89%IMCRImmunocore0.00%-8.61%+3.34%+6.64%-2.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYNDyne Therapeutics 3.06Buy$34.07159.48% UpsideETONEton Pharmaceuticals 3.00Buy$29.6762.07% UpsideHRMYHarmony Biosciences 3.00Buy$51.0056.82% UpsideIMCRImmunocore 2.45Hold$56.8974.59% UpsideCurrent Analyst Ratings BreakdownLatest ETON, DYN, HRMY, and IMCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/18/2025IMCRImmunocoreGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral9/4/2025IMCRImmunocoreZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/25/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$31.00 ➝ $35.008/25/2025IMCRImmunocoreJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.008/6/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$34.00 ➝ $13.007/31/2025DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$66.00 ➝ $36.007/29/2025DYNDyne TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $23.007/29/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$37.00 ➝ $31.007/29/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $38.007/21/2025HRMYHarmony BiosciencesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.007/15/2025DYNDyne TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$10.00 ➝ $9.00(Data available from 9/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/AETONEton Pharmaceuticals$58.18M8.44N/AN/A$0.94 per share19.47HRMYHarmony Biosciences$772.53M2.42$2.99 per share10.88$11.56 per share2.81IMCRImmunocore$356.15M4.61N/AN/A$7.20 per share4.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)ETONEton Pharmaceuticals-$3.82M-$0.16N/A36.61N/A-7.10%-0.73%-0.22%11/11/2025 (Estimated)HRMYHarmony Biosciences$145.49M$3.1010.4810.460.3823.44%26.34%17.71%11/4/2025 (Estimated)IMCRImmunocore-$51.09M-$0.40N/AN/AN/A-5.70%-5.40%-1.93%11/5/2025 (Estimated)Latest ETON, DYN, HRMY, and IMCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ETONEton Pharmaceuticals-$0.01-$0.10-$0.09-$0.10$16.71 million$18.93 million8/7/2025Q2 2025IMCRImmunocore-$0.21-$0.20+$0.01-$0.20$122.96 million$130.65 million8/5/2025Q2 2025HRMYHarmony Biosciences$0.78$0.68-$0.10$0.68$204.37 million$200.49 million7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDYNDyne TherapeuticsN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYNDyne Therapeutics0.1716.8316.83ETONEton Pharmaceuticals1.141.771.16HRMYHarmony Biosciences0.203.843.80IMCRImmunocore1.015.895.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYNDyne Therapeutics96.68%ETONEton Pharmaceuticals27.86%HRMYHarmony Biosciences86.23%IMCRImmunocore84.50%Insider OwnershipCompanyInsider OwnershipDYNDyne Therapeutics14.14%ETONEton Pharmaceuticals16.03%HRMYHarmony Biosciences23.60%IMCRImmunocore10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYNDyne Therapeutics100142.26 million122.15 millionOptionableETONEton Pharmaceuticals2026.82 million22.52 millionOptionableHRMYHarmony Biosciences20057.53 million43.96 millionOptionableIMCRImmunocore32050.39 million45.15 millionOptionableETON, DYN, HRMY, and IMCR HeadlinesRecent News About These CompaniesImmunocore's (IMCR) Neutral Rating Reiterated at GuggenheimSeptember 19 at 9:53 AM | marketbeat.comImmunocore assumed with a Neutral at GuggenheimSeptember 17 at 8:50 PM | msn.comInsider Selling: Immunocore (NASDAQ:IMCR) Insider Sells 22,532 Shares of StockSeptember 17 at 5:21 PM | marketbeat.comDavid Berman Sells 22,532 Shares of Immunocore (NASDAQ:IMCR) StockSeptember 17 at 6:02 AM | insidertrades.comImmunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $56.89 Consensus PT from AnalystsSeptember 15, 2025 | americanbankingnews.comAssessing Immunocore Holdings (NasdaqGS:IMCR) Valuation Following Recent Share Price MomentumSeptember 14, 2025 | finance.yahoo.comImmunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of "Hold" by AnalystsSeptember 14, 2025 | marketbeat.comImmunocore Holdings Plc (IMCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.comCubist Systematic Strategies LLC Trims Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCRSeptember 9, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Downgraded by Zacks Research to "Hold"September 8, 2025 | marketbeat.comBanque Transatlantique SA Invests $278,000 in Immunocore Holdings PLC Sponsored ADR $IMCRSeptember 7, 2025 | marketbeat.comCheckpoint Capital L.P. Buys Shares of 9,011 Immunocore Holdings PLC Sponsored ADR $IMCRSeptember 6, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Stock Price Up 7.4% - Should You Buy?September 5, 2025 | marketbeat.comImmunocore to present at upcoming investor conferencesSeptember 4, 2025 | globenewswire.comFrazier Life Sciences Management L.P. Grows Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCRSeptember 4, 2025 | marketbeat.comBaker BROS. Advisors LP Purchases 807,338 Shares of Immunocore Holdings PLC Sponsored ADR $IMCRSeptember 4, 2025 | marketbeat.comArmistice Capital LLC Sells 222,000 Shares of Immunocore Holdings PLC Sponsored ADR $IMCRSeptember 2, 2025 | marketbeat.comJefferies Financial Group Initiates Coverage on Immunocore (NASDAQ:IMCR)August 27, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Buys 351,610 Shares of Immunocore Holdings PLC Sponsored ADR $IMCRAugust 23, 2025 | marketbeat.comImmunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of "Moderate Buy" by AnalystsAugust 19, 2025 | marketbeat.comImmunocore’s Earnings Call Highlights Robust Growth and Strategic ExpansionAugust 13, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeETON, DYN, HRMY, and IMCR Company DescriptionsDyne Therapeutics NASDAQ:DYN$13.13 -0.79 (-5.68%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Eton Pharmaceuticals NASDAQ:ETON$18.30 -0.16 (-0.84%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Harmony Biosciences NASDAQ:HRMY$32.52 -0.11 (-0.33%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Immunocore NASDAQ:IMCR$32.58 -0.84 (-2.50%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FedEx Delivers Good News: The Bottom Is in for This Stock The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? McDonald’s: New All-Time Highs Are Inevitable Workday Rising… To Fresh Record High Stock Prices 3 Reasons Amazon Could Be at an All-Time High by October Joby's Stock Is Quiet, But Its Commercial Engine Is In Overdrive NIO's New Dawn: Why Wall Street's Bullish Turn Signals a Comeback Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
